Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists bind to dopamine receptors in the chemoreceptor trigger zone, preventing dopamine-receptor interaction. This inactivates the receptors and reduces signal transmission to the vomiting center, effectively suppressing the vomiting reflex triggered by chemotherapy. This mechanism makes them key antiemetic agents in cancer treatment.

Dopamine receptor antagonists include phenothiazines like prochlorperazine, butyrophenones such as droperidol, benzamides including metoclopramide, and thienobenzodiazepines like olanzapine. Each class offers distinct advantages: phenothiazines work against low to moderate emetogenic chemotherapy, while olanzapine prevents delayed vomiting post-chemotherapy. These diverse options allow tailored antiemetic selection.

Metoclopramide, a substituted benzamide, demonstrates dual functionality by blocking dopamine receptors to prevent vomiting and increasing gastric motility to treat gastroparesis. This combination makes it effective for both chemotherapy-induced nausea and gastrointestinal disorder-related emesis, providing therapeutic benefit beyond antiemetic action alone.

Phenothiazines like prochlorperazine and promethazine block dopamine, histamine, and muscarinic receptors simultaneously. This multi-receptor blockade makes them effective not only for chemotherapy-induced vomiting but also for motion sickness and gastrointestinal disorder-related emesis. Their versatility extends their clinical utility across multiple nausea-inducing conditions.

Olanzapine, a thienobenzodiazepine, inactivates both dopamine D2 and serotonin receptors. This dual-receptor inhibition prevents delayed nausea and vomiting associated with chemotherapy, making it particularly valuable for managing post-chemotherapy emesis that occurs hours or days after treatment. Its unique mechanism addresses delayed symptoms effectively.

Central dopamine antagonists can cause significant adverse effects including sedation, hypotension, dystonia, and cardiac arrhythmias. Extrapyramidal symptoms such as restlessness, dystonias, and Parkinsonian symptoms may also occur with prolonged use. Careful patient monitoring and dose adjustment are essential to balance antiemetic benefits against these potentially serious adverse effects.

Butyrophenones such as droperidol are administered intramuscularly or intravenously to control acute chemotherapy-induced emesis, unlike phenothiazines which are available as tablets, injectables, or suppositories. This parenteral route makes butyrophenones suitable for rapid antiemetic action in acute clinical settings where immediate symptom control is necessary.